Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Borderline Ovarian Mucinous Tumor: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Borderline Ovarian Mucinous Tumor: 1 US clinical trial tracked, none currently recruiting.

Borderline Ovarian Mucinous Tumor is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 1 of these trials.

Enrollment posture brief

Registry condition borderline-ovarian-mucinous-tumor

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Borderline Ovarian Mucin (th…0%
Open-enrollment share among volume-matched conditions near Borderline Ovarian Mucinous Tumor

Borderline Ovarian Mucinous Tumor has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Borderline Ovarian Mucinous Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Borderline Ovarian Mucinous Tumor is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Borderline Ovarian Mucinous Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bevacizumab Biological
1 trials
Laboratory Biomarker Analysis Other
1 trials
Oxaliplatin Drug
1 trials
Capecitabine Drug
1 trials
Carboplatin Drug
1 trials

US sites by state

Facility locations filed on Borderline Ovarian Mucinous Tumor trials. A trial with sites in several states counts in each.

California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Borderline Ovarian Mucinous Tumor page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Borderline Ovarian Mucinous Tumor trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • National Cancer Institute (NCI) sponsors the most Borderline Ovarian Mucinous Tumor trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Borderline Ovarian Mucinous Tumor condition card totals 1 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.